SAN DIEGO, Feb. 8, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present new
clinical data on ImmunoPulse® IL-12, its lead program
focused on oncology, at the upcoming 2017 American Association for
Cancer Research & Society for Immunotherapy of Cancer
(ASCO-SITC) Clinical Immuno-Oncology Symposium. In addition,
Punit Dhillon, President & CEO,
will present a corporate overview at two investment conferences in
February, including: the 19th Annual BIO CEO & Investor Conference and Source
Capital Group's 2017 Disruptive Growth & Healthcare
Conference.
2017 ASCO-SITC Clinical Immuno-Oncology
Symposium
Dr. Alain
Algazi, Associate Clinical Instructor, Department of
Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen
Diller Family Comprehensive Cancer Center, will present an oral and
poster presentation at the ASCO-SITC Clinical Immuno-Oncology
Symposium to be held on February 23-24,
2017, in Orlando, FL.
Details of the presentation are as follows:
Abstract Title: Immune monitoring outcomes of patients
with stage III/IV melanoma treated with a combination of
pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)
(Abstract ID #78)
Session Title: Activating the Immune System-New Clinical
Approaches
Date and Time: February 23,
2017 at 11:30 a.m. –
1:00 p.m. (poster) & 3:30 p.m. – 5:00 p.m.
EST (oral)
Location: Hyatt Regency Orlando
Further details on this ASCO-SITC oral and poster presentation
will be provided in upcoming Company communications. For more
information about this symposium, please visit:
http://immunosym.org/
The 19th Annual BIO
CEO & Investor Conference
Mr. Dhillon will
present a corporate overview at The 19th Annual
BIO CEO & Investor Conference on
February 14 at 3:00 p.m. EST at The Waldorf Astoria in
New York City.
To view to the live webcast, please access the following link at
the time of the presentation:
http://www.veracast.com/webcasts/bio/ceoinvestor2017/98226117037.cfm.
An archived version of the webcast will be available for 90 days on
OncoSec's website: http://www.oncosec.com.
For more information about this conference, please visit:
https://www.bio.org/events/bio-ceo-investor-conference
Source Capital Group's 2017 Disruptive Growth &
Healthcare Conference
Mr. Dhillon will present a
corporate overview at Source Capital Group's 2017 Disruptive Growth
& Healthcare Conference on February
15 at 3:00 p.m. EST at Convene
in New York City.
For more information about this conference, please visit:
www.DisruptNYC.com.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse®,
for the treatment of cancer. ImmunoPulse® is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse® IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various solid
tumors as well as a systemic immune response. OncoSec's lead
program, ImmunoPulse® IL-12, is currently in clinical development
for metastatic melanoma and triple-negative breast cancer. The
program's current focus is on the significant unmet medical need in
patients with melanoma who are refractory or non-responsive to
anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the
Company is also identifying and developing new immune-targeting
agents for use with the ImmunoPulse® platform. For more
information, please visit www.oncosec.com.
CONTACT:
Punit Dhillon
President & Chief Executive Officer
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Media:
Laura Radocaj
Dian Griesel Int'l.
212-825-3210
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-new-clinical-data-from-phase-2-combination-study-at-asco-sitc-clinical-immuno-oncology-symposium-and-corporate-updates-at-two-investment-conferences-in-february-300403831.html
SOURCE OncoSec Medical Incorporated